Quantitation of amyloid beta peptides Aβ1-38, Aβ1-40, and Aβ1-42 in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry

Analytical Biochemistry

Volumn 419, Issue 2, 2011, Pages 133-139

  Lame, Mary E ^a   Chambers, Erin E ^b   Blatnik, Matthew ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b WATERS CORPORATION   (United States)

Author keywords

Alzheimer's disease (AD); Amyloid beta (A ); Cerebrospinal fluid (CSF); Mass spectrometry (MS); Quantitation; Solid phase extraction (SPE); Ultra performance liquid chromatography (UPLC)

Indexed keywords

BRAIN; CEREBROSPINAL FLUID; DRUG PRODUCTS; GLYCOPROTEINS; HIGH PRESSURE LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; NEGATIVE IONS; NEURODEGENERATIVE DISEASES; PEPTIDES; PHASE SEPARATION; POSITIVE IONS; QUALITY CONTROL; RAT CONTROL;

ALZHEIMER'S DISEASE; AMYLOID BETAS; CEREBRO SPINAL FLUIDS; QUANTITATION; SOLID-PHASE EXTRACTION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EXTRACTION;

AMYLOID A PROTEIN; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANION; UNCLASSIFIED DRUG;

ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CROSS REACTION; EXTRACTION; HUMAN; IMMUNOASSAY; IMMUNOCHEMISTRY; LABOR; MOLECULAR DYNAMICS; MULTIPLE REACTION MONITORING; PEPTIDE ANALYSIS; PRIORITY JOURNAL; QUALITY CONTROL; SOLID PHASE EXTRACTION; STANDARD; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

RATTUS;

EID: 80054084612     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2011.08.010     Document Type: Article

References (27)

1. G.G. Glenner, and C.W. Wong Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein Biochem. Biophys. Res. Commun. 120 1984 885 890
2. P. Seubert, C. Vigo-Pelfrey, F. Esch, M. Lee, H. Dovey, D. Davis, S. Sinha, M. Schlossmacher, J. Whaley, and C. Swindlehurst Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids Nature 359 1992 325 327
3. L.K. Thompson Unraveling the secrets of Alzheimer's β-amyloid fibrils Proc. Natl. Acad. Sci. USA 100 2003 383 385
4. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, J. Cummings, A. Delacourte, D. Galasko, S. Gauthier, G. Jicha, K. Meguro, J. O'brien, F. Pasquier, P. Robert, M. Rossor, S. Salloway, Y. Stern, P.J. Visser, and P. Scheltens Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol. 6 2007 734 746
5. C.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, M.A. Mintun, M.J. Pontecorvo, F. Hefti, A.P. Carpenter, M.L. Flitter, M.J. Krautkramer, H.F. Kung, R.E. Coleman, P.M. Doraiswamy, A.S. Fleisher, M.N. Sabbagh, C.H. Sadowsky, P.E. Reiman, S.P. Zehntner, D.M. Skovronsky, for AV45-A07 Study Group, Use of florbetapir-PET for imaging β-amyloid pathology, JAMA 305 (2011) 275-283.
6. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 2002 353 356
7. C.A. Lemere, A. Beierschmitt, M. Iglesias, E.T. Spooner, J.K. Bloom, J.F. Leverone, J.B. Zheng, T.J. Seabrook, D. Louard, D. Li, D.J. Selkoe, R.M. Palmour, and F.R. Ervin Alzheimer's disease Aβ vaccine reduces central nervous system Aβ levels in a non-human primate, the Caribbean vervet Am. J. Pathol. 165 2004 283 297
8. K.A. Bates, G. Verdile, Q.X. Li, D. Ames, P. Hudson, C.L. Masters, and R.N. Martins Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests Mol. Psychiatry 14 2009 469 486
9. R. Motter, C. Vigo-Pelfrey, D. Kholodenko, R. Barbour, K. Johnson-Wood, D. Galasko, L. Chang, B. Miller, C. Clark, and R. Green Reduction of β-amyloid peptide-42 in the cerebrospinal fluid of patients with Alzheimer's disease Ann. Neurol. 38 1995 643 648
10. N. Ida, T. Hartmann, J. Pantel, J. Schröder, R. Zerfass, H. Förstl, R. Sandbrink, C.L. Masters, and K. Beyreuther Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay J. Biol. Chem. 271 1996 22908 22914
11. T. Oe, B.L. Ackermann, K. Inoue, M.J. Berna, C.O. Garner, V. Gelfanova, R.A. Dean, E.R. Siemers, D.M. Holtzman, M.R. Farlow, and I.A. Blair Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry Rapid Commun. Mass Spectrom. 20 2006 3723 3735
12. V.L. Villemagne, K.A. Perez, K.E. Pike, W.M. Kok, C.C. Rowe, A.R. White, P. Bourgeat, O. Salvado, J. Bedo, C.A. Hutton, N.G. Faux, C.L. Masters, and K.J. Barnham Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease J. Neurosci. 30 2010 6315 6322
13. S. Takeda, N. Sato, H. Rakugi, and R. Morishita Plasma β-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease Mol. Biosyst. 6 2010 1760 1766
14. K.G. Mawuenyega, W. Sigurdson, V. Ovod, L. Munsell, T. Kasten, J.C. Morris, K.E. Yarasheski, and R.J. Bateman Decreased clearance of CNS β-amyloid in Alzheimer's disease Science 330 2010 1774
15. M. Bidlingmaier, and C.J. Strasburger Growth hormone assays: current methodologies and their limitations Pituitary 10 2007 115 119
16. M.J. Ford, J.L. Cantone, C. Polson, J.H. Toyn, J.E. Meredith, and D.M. Drexler Qualitative and quantitative characterization of the amyloid beta peptide (Aβ) population in biological matrices using an immunoprecipitation-LC/MS assay J. Neurosci. Methods 168 2008 465 474
17. M.A. Findeis The role of amyloid beta peptide 42 in Alzheimer's disease Pharmacol. Ther. 116 2007 266 286
18. V. Welge, O. Fiege, P. Lewczuk, B. Mollenhauer, H. Esselmann, H.W. Klafki, S. Wolf, C. Trenkwalder, M. Otto, J. Kornhuber, J. Wiltfang, and M. Bibl Combined CSF tau, p-tau181, and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease J. Neural Transm. 116 2009 203 212
19. R. Goda, H. Masumoto, O. Okazaki, and K. Sudo Development of a pretreatment method for amyloid beta-protein analysis based on the effect of acetic acid on the dissolution of plasma polypeptides Biomed. Chromatogr. 22 2008 1279 1287
20. T.A. Lanz, and J.B. Schachter Solid-phase extraction enhances detection of β-amyloid peptides in plasma and enables Aβ quantification following passive immunization with Aβ antibodies J. Neurosci. Methods 169 2008 16 22
21. L. Dillen, W. Cools, L. Vereyken, and P. Timmerman A screening UHPLC-MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species Bioanalysis 3 2011 45 55
22. Z. Wu, W. Gao, M.A. Phelps, D. Wu, D.D. Miller, and J.T. Dalton Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry Anal. Chem. 76 2004 839 847
23. N.B. Cech, and C.G. Enke Effect of affinity for droplet surfaces on the fraction of analyte molecules charged during electrospray droplet fission Anal. Chem. 73 2001 4632 4639
24. 42 levels precede cognitive decline Neurology 65 2005 323 325
25. 40 ratio, and total tau Neurobiol. Aging 25 2004 273 281
26. M.B. Podlisny, D.R. Tolan, and D.J. Selkoe Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease Am. J. Pathol. 138 1991 1423 1435
27. T. Yamada, H. Sasaki, H. Furuya, T. Miyata, I. Goto, and Y. Sakaki Complementary DNA for the mouse homolog of the human amyloid beta protein precursor Biochem. Biophys. Res. Commun. 149 1987 665 671